May 17, 2022

Keith Cummings Chief Financial Officer PLIANT THERAPEUTICS, INC. 260 Littlefield Avenue South San Francisco, CA 94080

Re: PLIANT

THERAPEUTICS, INC.

Dear Mr. Cummings:

 $\label{eq:weak_problem} \mbox{We have limited our review of your filing to the financial statements and related}$

disclosures and have the following comments. In some of our comments, we may ask you to

provide us with information so we may better understand your disclosure.

 $\hbox{ Please respond to these comments within ten business days by providing the requested } \\$

information or advise us as soon as possible when you will respond. If you do not believe our $% \left(1\right) =\left(1\right) +\left(1$

comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Form 10-K filed March 1, 2022

Item 9A, page 135

1. Please file the audit report on internal controls as required by Item 308(b) of Regulation S- $\mbox{\sc K}.$

 $\,$ $\,$ In closing, we remind you that the company and its management are responsible for the

accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or $% \left(1\right) =\left(1\right) +\left(1\right)$

absence of action by the staff.

You may contact Al Pavot at (202) 551-3738 or Terence O'Brien at (202) 551-3355 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences